• Genentech Inc., of South San Francisco, plans to begin distributing a new 6 mg/mL Tamiflu for oral suspension this month following labeling changes. The new FDA-approved label calls for a change in the concentration of Tamiflu from 12 mg/mL to 6 mg/mL to reduce the possibility of prescribing and dosing confusion. The lower concentration is less likely to become frothy when shaken, which helps to ensure an accurate measurement, the FDA said. The 12 mg/mL product will remain on the market until current supplies expire.

• Generex Biotechnology Corp., of Worcester, Mass., published studies showing that CD4+ T-cell (T-helper) activation by li-Key hybride excludes T regulatory (immune suppressor) cells. Activation of T regulatory cells may interfere with immunotherapy in cancer. The study was published in the Journal of Immunology.

• IBio Inc., of Newark, Del., disclosed successful production of human plasma proteins using its iBioLaunch technology. Human alpha 1-antitrypsin and human C1 esterase inhibitor were produced at high yield in green plants via iBioLaunch.

• MonoSol Rx LLC, of Warren, N.J., is making its anti-emetic product Zuplenz (ondansetron) available for licensing. The product has been approved by the FDA, and MonoSol has made a decision to reacquire commercial rights to the drug from Par Pharmaceutical Inc., of Woodcliff Lake, N.J.

• Multicell Technologies Inc., of San Diego, is sponsoring research at the University Health Network Toronto General Hospital to evaluate its candidates MCT-465 and MCT-485 for primary liver cancer. The University scientists will use in vitro models to study the drugs' mechanisms of action and potential selective effects on liver cancer stem cells.

• Oxis International Inc., of Beverly Hills, Calif., formed a joint venture with John Repine, director of the Webb-Waring Center at the University of Colorado School of Medicine, to develop ergothioneine, a naturally occurring antioxidant, to treat and prevent acute lung injury, including acute respiratory distress syndrome. The joint venture has the rights to patent-pending technology created by Repine.

• Poniard Pharmaceuticals Inc., of San Francisco, adjourned its annual meeting until July 22 to get additional proxies to approve a reverse stock split in the range of 1-for-15 to 1-for-25 to regain compliance with Nasdaq's minimum $1 bid requirement. If the proposal isn't approved, the company said it could impact completion of its merger agreement with privately held Allozyne Inc., of Seattle. Shares of Poniard (NASDAQ:PARD) closed at 23 cents Monday. (See BioWorld Today, June 24, 2011.)

• Sunshine Biopharma Inc., of Montreal, reported that in a cytotoxicity study, it found that its lead compound Adva-27a is 16 times more effective against multidrug-resistant breast cancer cells than Etoposide. The drug was also unaffected by the molecular machinery thought to make cancer cells resistant to drugs.

• TcL Pharma SAS, of Nantes, France, changed its name to Effimune SAS. The firm is a spinout from the Institute of the Transplantation of Urology and Nephrology in Nantes and is developing preclinical immunomodulators for autoimmune and transplant indications.

• Vanda Pharmaceuticals Inc., of Rockville, Md., signed an exclusive license agreement with Probiomed SA de CV, a wholly owned unit of Mexico City-based Proquifin SA de CV, for the commercialization of schizophrenia drug Fanapt (iloperidone) in Mexico. Terms were not disclosed. Proquifin expects to apply for approval by the end of the year. Fanapt gained FDA approval in 2009 and is partnered with Basel, Switzerland-based Novartis AG.